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Abstract
Background: Molecularly-guided trials (i.e. PMed) now seek to aid clinical decision-making by matching cancer targets with
therapeutic options. Progress has been hampered by the lack of cancer models that account for individual-to-individual
heterogeneity within and across cancer types. Naturally occurring cancers in pet animals are heterogeneous and thus
provide an opportunity to answer questions about these PMed strategies and optimize translation to human patients. In
order to realize this opportunity, it is now necessary to demonstrate the feasibility of conducting molecularly-guided
analysis of tumors from dogs with naturally occurring cancer in a clinically relevant setting.
Methodology: A proof-of-concept study was conducted by the Comparative Oncology Trials Consortium (COTC) to
determine if tumor collection, prospective molecular profiling, and PMed report generation within 1 week was feasible in
dogs. Thirty-one dogs with cancers of varying histologies were enrolled. Twenty-four of 31 samples (77%) successfully met
all predefined QA/QC criteria and were analyzed via Affymetrix gene expression profiling. A subsequent bioinformatics
workflow transformed genomic data into a personalized drug report. Average turnaround from biopsy to report generation
was 116 hours (4.8 days). Unsupervised clustering of canine tumor expression data clustered by cancer type, but supervised
clustering of tumors based on the personalized drug report clustered by drug class rather than cancer type.
Conclusions: Collection and turnaround of high quality canine tumor samples, centralized pathology, analyte generation,
array hybridization, and bioinformatic analyses matching gene expression to therapeutic options is achievable in a practical
clinical window (,1 week). Clustering data show robust signatures by cancer type but also showed patient-to-patient
heterogeneity in drug predictions. This lends further support to the inclusion of a heterogeneous population of dogs with
cancer into the preclinical modeling of personalized medicine. Future comparative oncology studies optimizing the delivery
of PMed strategies may aid cancer drug development.
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Introduction
Novel approaches are needed to improve outcomes for cancer
patients. In the last decade, advances in biological platforms and
investigative tools have permitted the molecular characterization
of cancer in a clinically relevant setting. Indeed, the field of
personalized medicine (PMed) represents the integration of
genomic, proteomic and epigenetic data in the characterization
of a patient’s cancer [1,2,3,4]. Goals of personalized medicine are
to reveal unique disease drivers or susceptibilities, potential
toxicities, and resistance profiles and develop patient-specific
therapeutic interventions. Despite the promise in this approach,
many gaps remain in the determination of best practices, the
feasibility of real-time molecular profiling of patient samples in
support of therapeutic decision-making, and the actual clinical
benefit of these time-consuming and costly techniques.
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Molecular features of cancers have been the basis for selecting
specific treatments of patients for over a decade. Initial approaches
were candidate-based, such as the use of imatinib (Gleevec) for
acute myeloid leukemias harboring BCR-ABL gene translocations,
HER2Neu positive breast cancer treatment with trastuzumab
(Herceptin), and, prior to this, tamoxifen in ER/PR positive breast
cancer patients [5,6]. Such approaches represent some of the
earliest forms of molecularly guided therapy. In its current form,
PMed has evolved to represent a large-scale non-candidate based
assessment of a given cancer across the whole genome with greater
pharmacopeia coverage, rather than queries of specific candidate
analytes for a single disease-drug context [7,8]. It encompasses a
series of high throughput analyses such as gene expression, whole-
genome sequencing, whole exome-sequencing and epigenetic
assessments aimed to detail somatic and inherited mutations in
individual patients and their tumors. However, genome-wide
surveillance is complex and does not necessarily lead to a single or
defined intervention. Sophisticated mathematical algorithms are
needed to integrate these large pools of molecular data and then
match or identify appropriate or reasonable therapeutic approach-
es. Examples of non-candidate PMed clinical studies have been
reported. The Bisgrove trial, conducted by Von Hoff et al., treated
66 patients with refractory and metastatic cancers with regimens
chosen through immunohistochemical and gene expression
profiling of each patient’s tumor in conjunction with heuristic
biomarker rules based upon literature evidence [9]. Progression
free survival (PFS) improved compared to the immediate previous
regimen in 27% of patients [9]. Tsimberidou et al. described the
benefits of molecularly tailored therapy over non-molecularly
matched therapy with higher overall response rates (27% v. 5%),
longer time to treatment failure (median 5.2 v. 2.2 months), and
improved overall survival (median 13.4 v. 9 months) in Phase I
studies [10]. Other studies have similarly demonstrated the
feasibility and potential utility of PMed approaches in a variety
of clinical settings[11][12]. The early successes in proof-of-concept
trials with human patients emphasize the need to optimize various
aspects of PMed for broader clinical application. Examples of
areas in need of optimization include the improvement of sample
collection and processing techniques, the definition of molecular
features of patient samples, and the application of mathematical
algorithms to integrate these large pools of molecular data to
model relevant therapeutic approaches. The quantity and diversity
of available data coupled with differences in processing algorithms
can make it difficult to determine how to prioritize the links
between molecular targets and therapeutic agents [13]. Indeed,
comparisons between algorithms that seek to match targets with
therapeutics are needed. Conventional preclinical models of
cancer are not characterized by the individual-to-individual
heterogeneity seen in human cancers. As such there is limited
opportunity to use these preclinical models to effectively optimize
and translate components of PMed. Furthermore, it is unlikely that
such optimization of PMed can be accomplished in human trials
alone.
Comparative oncology is most often used to describe the study
of cancer biology and therapy in pet animals that naturally
develop cancer [14,15,16]. The heterogeneity and complexity of
cancer in the pet dog population and within cohorts of dogs with
the same histological diagnoses is well suited for modeling PMed.
The public availability of a progressively annotated canine genome
and the advent of high throughput genomic techniques for the dog
has enabled comparative oncology to describe canine cancer
biology and define potential therapeutic targets in many of the
same ways as human cancers [17]. In addition, strong cancer
breed predilections support ‘breed-based’ germ-line discoveries
that may streamline the definition of specific cancer targets as
‘‘drivers’’ of a cancer event. Since comparative oncology modeling
does not require up-front treatment with specific cancer treatment
regimens, novel therapeutic agents can be offered through clinical
trials at any stage in cancer presentation. Compressed disease
progression times in pet dogs with cancer allow for the evaluation
of a variety of PMed interventions against longitudinal endpoints
of cancer progression in ways not possible in the human clinic.
Finally comparative oncology randomized control trials can be
conducted in the newly-diagnosed, adjuvant (i.e. minimal residual
disease) and metastatic settings, evaluating the utility of PMed
drug selection and algorithm prediction across a range of clinical
scenarios.
To begin to realize these opportunities to model PMed
strategies, a proof of concept study was conducted through the
Comparative Oncology Trials Consortium (COTC) to determine
if the collection and analysis of tumor samples from dogs with
cancer, within a PMed framework, could be completed in a time
period (,1 week) considered feasible for implementation in a
future therapeutic trial. Tumor biopsies across multiple histologies
and in cohorts of canine bladder transitional cell carcinoma
(TCC), lymphoma, and melanoma were collected and quality
assurance/control measures applied to each step in the process of
generating molecular data to support a PMed derived therapeutic
report. The results revealed that high-quality, prospective tumor
collections, and large-scale target/drug identification studies in
canine cancers are feasible. As observed in human PMed trials,
tumor gene expression signatures in dogs cluster by cancer type,
whereas the personalized drug reports were uniquely patient
defined. Data from this study serves as rationale to now include
dogs with spontaneous cancers in the advancement and optimi-
zation of PMed for human patients.
Results
Study Enrollment
The study design (Table 1: Study Schedule) provided for
prospective tumor collection and real-time molecular profiling in
dogs with cancer. A total of 31 dogs were enrolled and assigned to
one of four cohorts. The first cohort was open to all cancer types
(n = 15 enrolled, 10 samples passed QA/QC), while the remaining
three cohorts were breed and/or cancer type specific. The cancer
type specific cohorts included Scottish terriers with bladder
transitional cell carcinoma (n = 5 enrolled, 4 passed QA/QC),
golden retrievers with lymphoma (n = 5 enrolled, 5 passed
QA/QC), and American cocker spaniels with melanoma. The
melanoma cohort was opened to all breeds after three months to
enhance accrual (n = 6 enrolled, 5 passed QA/QC). Age (range:
5.1–13.4 years, median 9.7 years), sex (18 spayed females, 1 intact
female, 9 castrated males, 3 intact males) and breed (5 mixed-
breed and 26 purebred) were recorded variables for all dogs
enrolled (Table 2: Study Cohorts). The trial opened on May
11, 2011 and closed on October 19, 2011 upon achieving its
accrual goals. There were no significant adverse events reported
(according to VCOG-CTCAE convention) [18].
Quality Assessment/Quality Control measures were
successful in defining high quality tumor samples for
expression analysis
Histopathology quality assurance and control (QA/QC) assess-
ment of all biopsies were performed by one pathologist (EJE).
Twenty-four of 31 cases enrolled (77%) passed QA/QC with an
average tumor surface area of 75–100%, tumor nuclei of 75–
100%, and necrosis , or equal to 10%. (Table 2: Study
Comparative Optimization of Precision Medicine
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Cohorts) Reasons for histopathology QA/QC failures included
samples with too little viable tumor, high degree of necrosis, small
sample size, or non-cancer diagnosis (Table 3: Reasons
samples failed QA/QC).
RNA isolation and QA/QC assessment was performed for all
enrolled cases (n = 31) at a Clinical Laboratory Improvement
Amendments (CLIA) accredited facility (Clinical Reference
Laboratory, Lenexa, KS) to ensure quality laboratory testing.
QA/QC standards defined here have been previously used for the
conduct of human tissue processing and clinical trials (http://
wwwn.cdc.gov/clia) [19]. Quality measures for RNA isolation
were quantity (total yield .20 ng) and integrity (A260/A280$1.8,
RIN$8.0) measured by Nanodrop and Agilent Bioanalyzer
respectively. Thirty of the 31 cases (96.78%) passed RNA QA/
QC. One sample (0507) failed QA/QC due to poor RNA quality
(low RIN score = 2.60), likely due to its abundant connective tissue
component (Figure 1 and Table 3: Reasons samples failed
QA/QC). Finally, cDNA was then amplified for all remaining
samples. Quality control for amplified cDNA included isolation
quantity (total yield $5 ug) and integrity (260/280$1.8); all 30
samples passed cDNA assessment.
Each case underwent the above described histopathologic and
RNA/cDNA evaluations. Samples (n = 24/31) that passed all
stages of QA/QC were analyzed for gene expression on an
Affymetrix platform (Canine Genome v 2.0). Common reasons for
QA/QC failures were small specimens or specimens with an
inadequate amount of viable tumor present (Table 3: Reasons
samples failed QA/QC). These results are consistent with those
of tissues collected for human PMed trials.
Bioinformatics analyses utilized genomics data to
generate individual patient personalized medicine
reports within a clinically relevant time frame
Gene expression data from each tumor was compared to that of
a reference gene set to define a relative gene expression profile.
The reference set consisting of forty normal canine tissues was
used to estimate variance in gene expression across normal
physiology [20]. Each gene probeset was represented by a z-score
depicting its tumoral expression in terms of the number of
standard-deviations from the mean expression of that probe set in
the reference data. Genes with a positive z-score in the tumor were
thereby over-expressed whereas those with a negative z-score were
under-expressed. Expression data was then analyzed by six
predictive methodologies (Drug Target Expression, Drug Re-
sponse Signatures, Drug Sensitivity Signatures, Network Target
Activity, Biomarker-Based-Rules-Sensitive, Biomarker-Based-
Rules-Insensitive) to identify potential therapeutic agents for
consideration (Figure 2) according to a previously-elucidated
workflow [19]. Drug sensitivity was ranked by z-score and p values
were transformed (2log(p)) and reported individually for each
specific algorithm then summated (sum of (2log(p) across
algorithms) to provide an overall prediction of drug selection. A
summary table and drug method comparison defined the top
selected agents (Table S1). The summary gives more weight to
drugs suggested by more than one algorithm. PMed reports were
not intended to be used therapeutically in this pilot study, although
their timely generation demonstrated the bioinformatics feasibility
to use the dog as a model for future PMed clinical trials.
The minimum feasible clinical time line (time from sample
ascertainment and shipment from COTC site to completed PMed
report returned to attending clinician) was defined prior to study
initiation as 168 business hours (, or equal to 7 days) (Figure 3).
Turnaround time for all cases was faster than projected. It was less
than 5 business days (n = 24, 116.5 business hours (4.85 days) and
168.46 total total hours (7.01 days)). (Table 4: Clinical Turn
Around Time). Clinical turnaround time for case 0508 (TCC)
was an outlier (completed in 212 business hours). The expression
data was generated in 91 business hours (3.79 days), but there was
a delay in sending the PMed report to investigators. Its inclusion in
the analysis did not impact the study conclusions. Overall the
turnaround for sample analyses fit a relevant clinical window for
future comparative oncology trials to model human PMed
advancements.
Canine tumor samples clustered by cancer type but drug
reports were patient specific
To characterize the utility of the resultant canine tumor
expression data for future therapeutic consideration, clustering
analysis was performed. Multidimensional scaling (MDS) coordi-
nates were generated using individual tumor gene (mRNA)
expression and drug prediction scores. Consistent with others
efforts using MDS and principal component analysis (PCA) of
human tumors, gene expression in the dog tumors clustered by
cancer type (Figure 4). As expected, broad histologic categories
shared genomic signatures, with carcinomas (bladder TCC, nasal
carcinoma, hepatocellular carcinoma (HCC)), mesenchymal (soft
tissue sarcomas, hemangiosarcoma, histiocytic sarcoma, melano-
ma), and round cell (lymphoma) tumor samples clustering in
Table 1. Study Schedule.
ACTION ELIGIBILITY DAY 1
Tumor measurements (caliper or US
measurement (cm))
X
Physical Exam X X
Digital photo of tumor X
Serum, plasma collection X
Tumor Biopsy (frozen and formalin) X
Buccal/saliva sample collection X
doi:10.1371/journal.pone.0090028.t001
Table 2. Study Cohorts.
COHORT CASES ENROLLED CASES PASSING QA/QC
Scottish Terriers with Transitional Cell Carcinoma 5 4
Golden Retrievers with Lymphoma 5 5
Various breeds with Melanoma 6 5
Open histology (any breed/histology) 15 10
doi:10.1371/journal.pone.0090028.t002
Comparative Optimization of Precision Medicine
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subgroups. The single HCC sample was an outlier due to liver
specific genes being highly expressed with high variance relative to
other samples. Breed was analyzed as an independent variable in
tumor gene expression but did not influence clustering (Figure
S1). Both pure bred and mixed breed dog samples were grouped
by histologic description.
The second phase of MDS analysis used total nested PMed drug
score, a summation of individual method scores, to cluster
individual samples by drug susceptibility (Figure 5). The drug
pool available for this analysis included 184 FDA approved agents.
There was a weak association of drug calls with tumor type, but
also clear heterogeneity in drug prediction even within a defined
cancer type. Preliminary drug predictions based on individual
tumor characteristics support the use of PMed drug prescription in
future comparative oncology studies.
Discussion
In this study, our objective was to determine the feasibility of
real time transcriptome analysis of canine tumors as part of a
PMed strategy to allow selection of potentially active drugs for
personalized patient therapy. The timeline from tumor biopsy to
PMed report generation was ,5 business days, confirming the
practicality of prospective tumor collection, molecular profiling,
and generation of an actionable PMed report in dogs with cancer.
Tumor samples collected were of high quality measured by both
histopathologic and molecular standards of nucleic acid integrity
and yield.
MDS analysis revealed that canine tumor gene expression was
strongly tied to cancer type. Although the number of histologic
subgroups analyzed was small, the data was consistent. Addition-
ally, clustergram analysis of personalized drug reports across
samples demonstrated heterogeneity in predictions even within a
single cancer type. This lends support to the inclusion of dogs with
naturally occurring cancers in PMed preclinical studies, where
patient-to-patient variability within a given cancer type (histology)
exists. Indeed, review of the drug predictions derived from canine
expression studies includes several therapeutic agents that are
reasonably predicted to have efficacy in a given cancer (i.e.
mitoxantrone in lymphoma) as well as agents not commonly used
in that cancer but used in other cancer types (i.e. the knase
inhibitor sunitinib in bladder cancer), and also drugs that are not
commonly used in cancer patients (i.e. theophylline). This selection
of PMed derived agents, supports the over-riding premise of this
approach, since conventionally used drugs are included as options
(proof of concept), but is extended by agents that may not be
considered without this approach.
Breed and type-specific collections for Golden Retrievers with
lymphoma, Scottish terriers with TCC, and an open histology/
open breed cohort also allowed for comparisons across tumor type
and breed. Cancer type-defined clusters trumped breed associa-
tions. However it is possible that, if sequenced, tumor mutational
status might be more specifically descriptive of breed. Also of note,
accrual was slower for some breed and cancer type-specific cohorts
(notably American Cocker Spaniels with melanoma), and,
therefore subsequent breed based efforts require additional
large-scale incentivized accrual to be sustainable.
Companion animals with cancer have been increasingly used to
provide insight into tumor biology and in clinical studies of drug
development [15,21,22]. As noted above, this is particularly
germane to PMed where traditional rodent xenograft models do
not collectively represent the heterogeneity known to exist in a
population of human patients with a given histological diagnosis of
cancer [14,23]. Comparative models may address challenges in
the PMed field by providing both types of heterogeneity and as
such the opportunity to ask if PMed guided interventions are
associated with improved outcomes compared to conventional
approaches. Furthermore, since PMed algorithms often define
‘‘first,’’ ‘‘second,’’ ‘‘third’’ tier agents, comparative oncology trials
could test the clinical value of the first versus the second and third
agents. Such agents may be offered as front line therapy for dogs
with cancer alone or in combination with other cancer therapy.
Comparative oncology trials could also allow the comparison of
PMed algorithms (which are likely to be context-sensitive) through
head-to-head trials to define the most successful approaches or
scenarios for algorithm prescription[28]. With crossover rules for
progressive disease, novel trial designs may also allow the
evaluation of presumed ‘‘negative’’ (i.e. not predicted to be
effective) agents compared to presumed ‘‘positive) agents (i.e.
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predicted to be effective). Further, components of the PMed
approach may be individually tested and optimized through
comparative models. Points of optimization may include defining
the best sources of molecular data input, determining optimal
biopsy collection techniques, evaluating informed algorithm
generation, and exploring combinational therapy selection [26].
PMed comparative oncology studies are however limited by
challenges in the translation of genomic signatures across species.
For example, although there are data demonstrating similarities in
gene expression between canine and human cancer types, the use
of human expression signatures to query canine expression data is
not well-established [24,25][27]. Further, in the case of gene
expression data, the dearth of normal reference sets in compar-
ative species can present a challenge. In this report the use of a
canine normal tissue expression data set was utilized. Alternative
options for such reference sets may include expression data from
other tumor types. From the perspective that these analyses are
aimed at identification of key deregulation phenomena, we expect
that significant deregulation will be identified even when highly
variable reference sets of tumors are used. All methods begin with
basic z-scores and for genes that are deregulated these scores will
be very significant regardless of the reference. In support of this,
review of the drug selection data (Table S1) provides support for
the validity of this cross-species approach. For example, the drug
selection outcomes in canine lymphoma compared to other types
disproportionately include cytotoxic drugs that are conventionally
used to treat canine and human lymphoma. Similarly, the
transitional cell carcinoma of the bladder disproportionately
included several inhibitors of the cox-2 pathway. Interestingly
these agents have been shown to be active and are under
evaluation in canine and human bladder cancers.
Complex models are needed to effectively evaluate PMed study
designs and this proof of concept trial validates the dog with cancer
as a model for clinical evaluation of novel PMed approaches. It is
now reasonable that dogs with cancer can begin to fill the gap in
optimizing the delivery of these approaches for translation to
Figure 1. Histopathology and RNA quality assurance and control measures were successful in procuring high quality canine tumor
samples. Formalin-fixed, paraffin-embedded tumor biopsy samples were sectioned, paraffin embedded, and H&E stained for light microscopic
evaluation. A single board-certified veterinary pathologist (EJE) assessed % tumor surface area, % tumor nuclei and % tumor necrosis to determine
their quality prior to molecular profiling. Images of representative H&E images are shown: A. Sample 0209, a golden retriever with lymphoma, passed
QA/QC. (Tumor 75–100%, necrosis ,10%), while B. sample 0503, a beagle with lymphoma, failed QA/QC (Tumor 75–100%, necrosis .20%). Biopsies
that failed to pass QA/QC in any category were excluded from subsequent analysis. Additionally RNA isolation was performed for all enrolled cases
(n = 31) at a CLIA certified laboratory. RNA was extracted from Tumor A biopsy samples. Quality measures included quantity (total yield .20 ng) and
integrity (A260/A280.1.8, RIN.8.0) measured by Nanodrop and Agilent Bioanalyzer. Electropherograms from cases C. 0210 and D. 0507 are depicted.
Sample 0210, an oral melanoma, passed RNA QA/QC while sample 0507, a mast cell tumor, failed QA/QC (poor quality RNA due to a large connective
tissue component).
doi:10.1371/journal.pone.0090028.g001
Comparative Optimization of Precision Medicine
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human patients. Our study used operational, analytical and
clinical aspects of a comparative approach to identify potentially
active agents in spontaneously derived cancers. This study sets the
foundation for trials that will become more integrative and
comprehensive in nature though the generation and analysis of
multiple dimensions of genomic data in conjunction with
prospective clinical outcomes. Comparative oncology models have
the potential to expedite this evaluation and lead advancements in
personalized medicine.
Methods
Comparative Oncology Trials Consortium
The goals and infrastructure of the COTC have been previously
described [14,21,29]. All COTC trial data were reported
electronically and contemporaneously reviewed through the
Cancer Central Clinical Database (C3D), a controlled-access
database developed through the NCI’s Center for Cancer
Research (CCR) and Cancer Bioinformatics Grid (CaBIG) and
modified for use in canine clinical trials [30].
Study design and schedule
Client-owned pet dogs with histologically confirmed cancer,
favorable performance status (grade 0 or 1 modified Eastern
Cooperative Oncology Group (ECOG) performance status), and
informed owner consent were eligible for enrollment. Specific
subsets including Scottish terriers with transitional cell carcinoma
of the bladder, golden retrievers with multi-centric lymphoma and
all breeds with oral melanoma were eligible for enrollment.
Eligibility criteria required a tumor amenable to a peripheral
biopsy (except the cases with transitional cell carcinoma of the
bladder). Only dogs with naı̈ve disease were eligible for
enrollment. Physical examination and laboratory [complete
blood count (CBC), serum biochemical profile, urinalysis (UA)]
Figure 2. Bioinformatic analysis defines the platform for PMed report generation. Gene expression data from each tumor was compared
to a reference sample set (canine normal tissue compendium, GSE20113 from Gene Expression Omnibus) to obtain a relative gene expression profile.
Each gene probeset was represented by a z-score depicting its expression in the tumor in terms of the number of standard-deviations from the mean
expression in the reference set. In the iteration of the PMed tools used in this study, data were analyzed by six distinct predictive methodologies
(Drug Target Expression, Drug Response Signatures, Drug Sensitivity Signatures, Network Target Activity, Biomarker-Based-Rules-Sensitive,
Biomarker-Based-Rules-Insensitive) to identify (or exclude in the case of biomarker resistant rules) potential agents for consideration. All predictions
were based on the conversion of canine genomic data into human homologs (for both patient tumor samples and the reference set of normal
tissues) prior to the application of the specific algorithms that rely exclusively on human knowledge and/or empirical drug screens using human cell
lines (see Methods). While individual patient tumor PMed report generation and distribution was the final step in this process, this specific study did
not have therapeutic intent and drug prescription was not performed.
doi:10.1371/journal.pone.0090028.g002
Comparative Optimization of Precision Medicine
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evaluations were performed to evaluate eligibility prior to
enrollment. Exclusion criteria removed dogs with significant co-
morbidities (such as renal, liver, and heart failure or coagulopa-
thy), history of chemotherapy (including corticosteroids in
lymphoma cases and NSAIDs in TCC), radiation therapy or
immunotherapy. All dogs were evaluated uniformly and treated
within a defined clinical protocol with IACUC approval at each
COTC enrollment site (Colorado State University, Michigan State
University, Purdue University, Tufts University, University of
Georgia, University of Minnesota, and University of Wisconsin-
Madison). The NCI-Comparative Oncology Program (COP)
reviewed the eligibility screening and approved trial entry of each
patient. Potential adverse events related to the research protocol
were monitored according to accepted VCOG-CTCAE criteria
[18].
Patient and Sample Tracking by Wiki
Defining the clinical turnaround time for prospective gene
expression analysis and personalized medicine report generation
was a main objective of this study. The Confluence Enterprise
Wiki online database tracked the location of the specimens and
time spent at each step of the QA/QC process. Confluence
Enterprise Wiki was created by Atlassian and was utilized for this
study. Researchers involved in the study were given usernames
and passwords to access the common study site. At the start of the
study 4 tables, one for each cohort, were constructed on the wiki
space. When a patient enrolled, their patient ID, sex, date of birth,
breed, and tumor type were entered into the table by the study
monitor (CM). The specimens and results were tracked in real
time with each investigator entering the date and time a sample
arrived in their laboratory, when analysis began, and was
completed, as well as the sample results. The wiki space allowed
us to track the location of the specimens and derived data at each
step of the QA/QC process.
Figure 3. Expected clinical turnaround time for canine tumor sample collection, processing, expression, bioinformatic analysis and
PMed report delivery. The graphic defines the prospective timeline of key steps in the process of sample collection, shipment, histopathology and
RNA quality assurance and control assessments, expression profiling and PMed report generation. Samples were biopsied at their clinical COTC site,
sent to histopathology and CLIA labs for parallel sample and RNA QA/QC, Affymetrix gene expression analysis performed, and the derived genomic
data sent to the Van Andel Research Institute for bioinformatics evaluation and PMed report generation. Minimum feasible turnaround time for
sample analysis was described prospectively as 7 business days (168 hours), however all cases were completed in 4.85 days (116.46 hours). The
process was successful in defining high quality tissues for molecular analysis and will be used in future canine PMed comparative studies.
doi:10.1371/journal.pone.0090028.g003
Table 4. Clinical turn around time.
COHORT PATIENT NUMBER TOTAL TIME IN BUSINESS HOURS (DAYS) TOTAL TIME IN HOURS
Open histology 10 114.50 (4.77) 174.50
Lymphoma 5 117.00 (4.88) 165.00
TCC 4 116.75 (4.86) 158.75
Melanoma 5 119.60 (4.98) 167.60
All Cases* 24 116.46 (4.85) 168.46
*Clinical turnaround time for case 0508 (TCC) was an outlier (completed in 212 business hours).
The expression data was generated in 91 business hours (3.79 days) but there was a delay in the PMed report being sent to investigators. Overall the turn around for
sample analysis fits a clinical window and its inclusion in the analysis did not impact the study conclusions.
doi:10.1371/journal.pone.0090028.t004
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Sample Collections
Tumors. Tumor biopsies on Day 1 of the study were
required from all dogs. Tumors must have been at least 3 cm in
longest diameter to be eligible for biopsy. Biopsy techniques were
prospectively defined by standard operating procedures (SOPs)
and used uniformly at all participating COTC sites. Biopsies were
collected by either a 10–14 gauge Tru-cut instrument, 6 mm
punch biopsy, or an open biopsy technique. Biopsies for dogs with
transitional cell carcinoma were collected by cystoscope or
ultrasound guided. Two samples of at least 1 cm in length were
obtained at various planes within the tumor to capture natural
disease heterogeneity. The two planes were labeled as Tumor A
and Tumor B. Each of the sections were bisected equally. Tumor
A was divided and equal specimens placed in either RNAlater or
formalin. Tumor B was divided and equal specimens placed in
formalin or flash frozen. Tumor A samples (RNAlater) were
shipped overnight on a 220 C ice pack to the Clinical Reference
Laboratory (CRL) for RNA isolation. Tumor A and B samples
(formalin) were shipped overnight on a 220 C ice pack to
Colorado State University.
Plasma and serum. Plasma and serum samples were
collected for all patients by standardized procedures on Day 1.
These were flash frozen in liquid nitrogen and stored at 280 C. At
the end of the study samples were shipped overnight on dry ice to
the NCI-COP for permanent storage. These were stored for
potential post hoc secondary analyses.
Histopathology Review
Formalin-fixed, paraffin-embedded tumor biopsy samples were
routinely sectioned, paraffin embedded, and stained with H&E for
light microscopic evaluation. Histopathology quality assurance
and control (QA/AC) assessment for all biopsies were performed
by one pathologist (EJE). Data was subjectively classified into
ordinal catagories: % tumor surface area was defined as the
percentage surface area of each examined tissue that was
determined to be tumor; % tumor nuclei was defined as the
percentage of each examined tissue’s nuclei that were determined
to be tumor nuclei; % tumor necrosis was defined as the
percentage of each examined tumor that was determined to be
necrotic. Samples were evaluated for all 3 parameters (tumor
surface, nuclei, and necrosis) at both the top and bottom of the
tumor specimen and then averaged. Categories for percent tumor
surface area were 0%–24%, 25%–49%, 50%–74%, and 75–
100%. Categories for percent tumor nuclei were 0%–24%,
Figure 4. Cancer type defines canine tumor gene expression signatures. Multidimensional scaling (MDS) coordinates were generated using
individual tumor gene (mRNA) expression z-scores to define relationships within the dataset. Tumor gene expression clustered by tumor type.
Additionally, histologic categories share genomic signatures, with carcinomas (bladder TCC, nasal carcinoma, hepatocellular carcinoma (HCC)),
mesenchymal (soft tissue sarcomas, hemangiosarcoma, histiocytic sarcoma, melanoma), and round cell (lymphoma) tumors clustering together in
subgroups.
doi:10.1371/journal.pone.0090028.g004
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25%–49%, 50%–74%, and 75–100%. Categories for percent
tumor necrosis were ,10%, 10–20%, and .20%. Passing
parameters were considered . or equal to 75% tumor and , or
equal to 20% necrosis. Biopsies that failed to pass assessment were
excluded from the remainder of the study. Representative
microscopic images were captured for all examined samples and
banked for future use.
Total RNA Extraction
RNA isolation and QA/QC assessment from samples collected
in the study was performed at a Clinical Laboratory Improvement
Amendments (CLIA) accredited facility (Clinical Reference
Laboratory, Lenexa, KS) to ensure quality laboratory testing.
Standards defined here have been previously used for the conduct
of human tissue processing and clinical trials (http://wwwn.cdc.
gov/clia). RNA was extracted from canine tumor biopsy tissues
(Tumor A) taken on Day 1 of the study and stored in RNAlater
stabilization solution (Ambion, Cat # AM7020). The quality
measures for RNA isolation were quantity (total yield .20 ng) and
integrity (A260/A280$1.8, RIN$8.0) measured by Nanodrop and
Agilent Bioanalyzer respectively.
Canine Genome 2.0 Expression Analysis
cDNA synthesis and amplification were accomplished using the
NuGen Ovation Pico WTA System (Cat # 3300-12). Fifty
nanograms of total RNA was used for cDNA synthesis using the
following steps as per the Ovation Pico WTA System protocol:
First Strand cDNA synthesis, second strand cDNA synthesis,
cDNA purification, SPIA cDNA amplification, and amplified
SPIA cDNA purification. The amplified DNA was checked for
quality and quantity using the Nanodrop spectrophotometer.
cDNA samples with a 260/280 ratio of $1.8 and a concentration
above 5 mg in 30 ul were considered acceptable for further
processing using the Affymetrix Canine genome 2.0 array.
Amplified cDNA samples generated with the NuGen Ovation
Pico WTA system were used for fragmentation and labelling
process using the NuGen Encore Biotin Module (Cat # 4200-12).
The resulting fragmented and labeled cDNA was used for
Affymetrix Canine 2.0 array hybridization. The hybridized arrays
were washed and stained using GeneChip Hybridization, Wash
and Stain Kit (Affymetrix, Cat # 900720).
Initial QC analysis of the scanned array was accomplished using
the Affymetrix Expression Console Software. Background noise
,100, % present call $30%, scale factor 100 and appropriate
spike in control signals are necessary for adequate sample quality.
Upon passing all criteria, MAS5.0 processed .CEL and normal-
ized pivot .TXT files were extracted and deposited on a secure
FTP site at Van Andel Research Institute (VARI) for subsequent
analysis. This data has also been uploaded to GEO, accession
#GSE51131.
Bioinformatics
The general analytical workflow undertaken upon receipt of a
tumor-derived gene expression profile is shown diagrammatically
Figure 5. Drug prediction scores define individual tumor
predicted drug susceptibilities. A. MDS analysis shows nested
PMed summary drug scores cluster individual samples by drug
susceptibility. There was a weak association of drug calls with cancer
type, but clear heterogeneity in drug prediction even within a single
cancer type (histology). B. A heat map of targeted and conventional
agent sensitivity across each patient sample. Individualized drug
predictions based on tumor characteristics support the use of PMed
drug prescription in future comparative oncology studies.
doi:10.1371/journal.pone.0090028.g005
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in Figure 2 and is adapted from a workflow previously established
in human neuroblastoma [19]. Gene expression data from each
tumor was compared to a reference sample set in order to obtain a
relative gene expression profile [20]. Each gene probeset was
represented by a z-score depicting its expression in the tumor in
terms of the number of standard-deviations from the mean
expression in the reference set. The individual patient samples
from the canine Affymetrix array probesets were converted to z-
scores using a normal K-9 reference set based on the 39 samples in
GEO data set GSE20113. In the cases where multiple probesets
represented the same gene (Affymetrix canine 2.0 version 31
annotation) they were aggregated using the mean to a single value
for the appropriate Entrez gene identifier. The canine Entrez gene
identifiers were then converted to human Entrez ID’s using the
homolog data from the NCI database (ftp://ftp.ncbi.nih.gov/
pub/HomoloGene/current/homologene.data dated 11/15/
2010). Any canine ID’s that had ambiguity in the mapping to
human genes were removed and only values whose canine ID’s
exhibited clear and concise (one-to-one mapping from canine to
human genes) conversion to human ID’s were retained. The final
step in the conversion process was to convert the human Entrez
gene identifiers to the appropriate Affymetrix U133 Plus 2.0
probesets (U133 Plus 2.0 annotation version 31). Only concisely
mapped Entrez gene IDs to Affymetrix probesets were retained.
Use of the U133 Plus 2.0 probeset data facilitates the use of the
standard workflow and application of the previously-detailed
predictive methods developed for human subjects [19]. The
standard workflow is capable of utilizing z-Score values associated
with the U133 Plus 2.0 probesets. After this pre-processing step,
data was submitted to the following collection of predictive
methodologies to identify potential agents for consideration. All
predictions are based on canine genomic data (tumor and normal
tissues) but a human bioinformatics backbone as detailed:
Drug Target Expression. This first and most rudimentary
method utilizes a human drug-target (mechanism of action)
knowledge base and rules-based method to identify over-expressed
genes (z-score $+3) in a patient’s tumor that represent known
molecular targets of antagonists, then match the appropriate drug
from the knowledge base (example rule: IF EGFR Expression z-
score $+3 THEN INDICATE Cetuximab). Multiple sources of
public domain knowledge have been used to establish the
internally-curated drug-target knowledge base including Drug-
Bank, MetaCore (GeneGo-Thomson Reuters), MedTrack,
PharmGKB, UpToDate and DrugDex (Thomson Reuters)
[31,32]. These rules are subject to change based on review of
current literature evidence. Existing z-score thresholds of +3 or 23
were selected based on prior experience, but thresholds are
variable by rule and can be adjusted as needed. The p values are
derived from the z-score of the expression level used to trigger the
rule – the greater the z-score, the lower the p value associated with
the rule. 260 vetted drug-target rules covering 123 drugs across
260 unique targets were contained within the drug-target
knowledge base used in this study (Table S2).
Biomarker Rules. Much like target expression, this method
employs predefined and published rules maintained in a drug-
biomarker database mined from public knowledge in which the
efficacy of a specific drug has been associated with the expression
of a specific molecular marker [9]. However, this method not only
highlights drugs with predicted sensitivity, but also highlights drugs
that may be contraindicated (insensitive drugs) on the basis of
resistance rules (example rule: IF ERCC1 z-score $+3 THEN
CONTRAINDICATE Oxaliplatin). Further, this method can take
into account underexpressed genes (z-scores #23). Currently,
there are 34 biomarker rules indicating sensitivity to 14 FDA
approved drugs in this database. Combining sensitive and
resistance biomarker rules indicates 20 unique FDA approved
drugs within the drug-biomarker rules knowledge base (Table
S3).
Drug Response Signatures. This method reproduces the
Connectivity Map (CMAP) concept initially developed by the
Broad Institute in which the genomic consequence of drug
exposure is used to connect drug effect to disease signatures [33].
The hypothesis underlying this method is that drugs that reverse
the disease genotype (gene expression profile) towards normalcy
have the potential to reverse the disease phenotype. The CMAP
method is based on the exposure of four cell lines (MCF7, PC3,
HL60, and SKMEL5) to a series of 142 small molecules and
measurement of pre- and post-exposure gene expression profiles as
described in the above reference. For our purposes, over- and
under-expressed genes in the patient’s tumor (z-scores $+2.0 or
#22.0 respectively) are compared to every array in the CMAP
drug response signature database. Rank-based statistics are then
used to identify drugs with a significant inverse connectivity to the
disease genotype and to generate an enrichment score for each
gene in the list. The drug list is a subset derived from CMAP and
refined based on literature support (Table S4) and drug match
scores are calculated using Kolmogorov-Smirnov statistics with p-
values estimated using permutation testing with 50,000 permuta-
tions. Only those patterns that match with a p-value less than 0.05
are reported.
Drug Sensitivity Signatures. This method reproduces a
previously published implementation of the Parametric Gene Set
Enrichment Analysis (PGSEA) method using the NCI-60 cell line
sensitivity data provided in the COMPARE database [34,35,36].
Gene expression signatures from the untreated NCI-60 lines
associated with differential response to specific drugs on the basis
of IC-50s from an in vitro drug screen reported in the COMPARE
database are compared to the canine tumor-derived gene
expression signature (all probesets from one sample standardized
to z-score relative to the normal reference set) through the PGSEA
analysis tool which in this iteration utilizes a one sample t-test to
determine sensitivity to a subset of 11 drugs selected from the NCI-
60 list (Table S5). Each drug is assigned a p-value for predictive
efficacy and only those with a p-value less than 0.05 are reported.
This approach is consistent with well-published methods for
inferring drug sensitivity utilizing the NCI-60 cell line dataset
[35,36,37].
Network Target Activity. This method predicts the activity
(rather than expression) level of drug targets on the basis of a
specific type of molecular network analysis referred to as
topological analysis described previously [38]. This method utilizes
gene expression data and pre-requisite knowledge of protein-
protein interactions based on GeneGo topology analysis to predict
upstream target activity on the basis of observed downstream
transcriptional events selected from Affymetrix probes – either all
z-scores $2 or the top 200 overexpressed probes (K in formula
below). K thus represents a subset of a global interaction network
of size N. Construction of a directed shortest path network
connecting nodes from K to each other is performed utilizing the
MetaCore GeneGO database of over 200,000 protein-protein and
protein-small molecule interactions. The shortest path network, S,
is constructed by building directed paths from each node in K to
other nodes in K, traversing via other nodes in the global network
as necessary. The number of node pairs in the shortest path
network which are connected through each pair of nodes i and j is
determined (Kij). This process is repeated in the global network to
calculate the number of node pairs connected through nodes i and
j (Nij). The probability that the number of nodes would be Kij or
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larger given the size of the input network and the distribution of











Hereby, the analysis output is the probability that a given drug
target provides significant input to or output from a highly
connected network identified in each tumor. Calculated p values
are used to rank predictive scores and only those above 0.05 are
reported. Currently, this method attempts to predict the activity of
260 unique drug targets spanning 123 FDA human approved
drugs (Table S2).
Personal Medicine Report Generation
Upon execution of the different analytical methodologies, a
compiled report was generated. The personalized drug report
conveys the predicted efficacy (or resistance in the case of
biomarker resistance rules) of the drugs identified by each of the
methods described above. These reports contain a summary
section combining results of each method with scores that
represent stronger indications for drugs that were predicted by
multiple methods. These scores are adjusted for multiple methods
and are based on the sum of scores from individual methods. In
addition, each method contains scores reflecting the contribution
of multiple genes to the suggested therapy. Further, personalized
drug reports also associate public clinical and contextual
knowledge to show any evidence that may support the use of
the predicted drug in the context of the patient’s disease state.
The supporting evidence comes from a variety of sources
including PubMed, clinicaltrials.gov and DrugDex (Thomson
Reuters).
Clinical Turnaround Time Monitoring
All sample processing time points were recorded on the
COTC016 wiki page. This included the time of biopsy, time
shipped from COTC site and time tumor specimens arrived at the
Clinical Reference Laboratory (CRL) for expression analysis and
Colorado State University (CSU) for histopathology analysis. Also
included were the QA/QC analysis start and completion times at
the CRL and CSU. Each lab entered the results in the wiki and
uploaded data and/or representative images. All recorded times
were listed in their respective time zone. When calculating the
total elapsed time from biopsy shipment to PMed report
generation, all times were converted to EST then military time
for calculation purposes. Holiday and weekend hours were
subtracted from total times to calculate business hours necessary
for sample evaluation.
Gene Expression Cluster Analysis
mRNA expression values for each gene in the canine tumor
samples were normalized relative to the average expression of that
gene in 40 canine normal tissue samples from a reference set [20].
The tumor to normal ratio and standard deviation in the tumor
samples was used to calculate a z-score statistic for each gene
(mRNA) as described above in Bioinformatics. mRNA z-scores
and drug prediction scores for each sample were then used for
separate multidimensional scaling (MDS) analyses for each data
type. MDS coordinates were generated using the classical
multidimensional scaling (cmdscale) function of the R statistical
application (http://www.r-project.org; v2.14.1) based on sample
to sample distances calculated using Pearson’s correlation distance
(one minus Pearson’s correlation coefficient).
Supporting Information
Figure S1 Canine tumor gene expression signatures
cluster independently of breed. In a cursory evaluation of the
potential effect of breed on tumor classification in this limited
sample set, breed did not influence MDS analysis of gene
expression z-scores. Both pure bred and mixed breed dog samples
clustered by cancer type.
(TIF)
Table S1 Summary of drug predictions: Top drug
prediction by algorithm [2log(p) score] (Inferring
gene(s) where applicable). Drug recommendations based on
the six drug prediction methodologies are shown for each tumor
and includes the highest ranked recommended according to a
summary score. This summary score gives more weight to drugs
suggested by more than one algorithm.
(DOCX)
Table S2 Expression and network-based drugs and
targets. Two hundred and sixty unique drug targets for 123
FDA approved human are shown alongside supporting evidence
for the drug-target interactions that guideds4 inclusion in the
network-based prediction algorithm.
(DOCX)
Table S3 Biomarker rules. Thirty-four biomarker rules are
shown that match 20 FDA approved drugs to 22 targets according
to sensitivity or resistance alongside supporting evidence for these
interactions.
(DOCX)
Table S4 Response signature drugs. The subset of 107
CMAP drugs refined based on literature support and used to
match drugs based on disease genotypes.
(DOCX)
Table S5 Sensitivity profile drugs. The subset of 11 drugs
selected from the NCI-60 list COMPARE database and matched
to gene expression signatures.
(DOCX)
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